MORC2 gene changes and how they relate to nerve and developmental symptoms
Official title: Deciphering MORC2 Genotype/Phenotype Correlation to Improve Patient Diagnostic
Run by Hospices Civils de Lyon · NCT07038239 · Data updated 2026-11-12
This project will try to see if specific changes in the MORC2 gene explain why some people develop Charcot–Marie–Tooth nerve problems while others have broader developmental delays, growth impairment, facial differences, and neuropathy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 4 Years and up |
| Sex | All |
| Enrollment | 45 (estimated) |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 12 sites (Besançon and 11 other locations) |
| Status | Recruiting |
| Started | June 16, 2026 |
| Main results expected | June 2027 |
| Study ends | June 2027 |
| Registry record updated | June 18, 2026 |
| Trial ID | NCT07038239 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
People of any age who have a confirmed MORC2 mutation, can provide informed consent (or have guardian consent), and have undergone or can undergo EMG and biological sample collection are the intended participants.
✕Probably not a fit
Patients who lack a MORC2 mutation, have another identified genetic cause, refuse sample collection, or fall under the regulatory exclusions (for example pregnancy or legal deprivation of liberty) will not be eligible and are unlikely to benefit from this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational genotype–phenotype correlation project enrolling people with confirmed MORC2 mutations. Participants undergo clinical evaluation, electromyography (EMG) as available, and provide blood and skin biopsy samples for molecular studies. Investigators will compare clinical presentations across different MORC2 variants and examine how those variants affect MORC2-related functions such as ATPase activity and HUSH-complex–mediated chromatin silencing. The goal is to link specific genetic changes to the spectrum from isolated peripheral neuropathy to the broader DIFGAN phenotype.
Why it matters
Potential benefit: If successful, the findings could help clinicians predict prognosis and personalize monitoring for people with MORC2 mutations and point to molecular pathways for future therapies.
How similar studies have gone: Over 30 families with MORC2 mutations have been reported linking the gene to CMT and to broader DIFGAN presentations, but detailed genotype–phenotype mapping and mechanistic links via HUSH activity remain incompletely defined.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Presence of a mutation in the MORC2 gene, identified during an evaluation for peripheral neuropathy or intellectual disability * Patient has undergone electromyography (EMG) or is able to undergo EMG during the inclusion visit * Affiliation with the national health insurance system * Informed consent from the patient if an adult, or from parents/legal guardians if the patient is a minor Exclusion Criteria: * Presence of another mutation responsible for peripheral neuropathy or intellectual disability * Refusal to undergo biological sample collection * Regulatory exclusion criteria: * Pregnant, postpartum, or breastfeeding women * Individuals deprived of liberty by judicial or administrative decision * Individuals not affiliated with a social security system or not benefiting from an equivalent health coverage scheme
Where it's running
-
CHU de Besançon
Besançon, France Recruiting -
CHRU Brest
Brest, France Recruiting -
CHU Grenoble
Grenoble, France Recruiting -
CH de Versailles
Le Chesnay, France Recruiting -
Service de Génétique moléculaire, pharmacogénétique, hormologie Hôpital Bicêtre
Le Kremlin-Bicêtre, France Recruiting -
Hospices Civils de Lyon
Lyon, France Recruiting
Show 6 more locations
-
CHU Marseille
Marseille, France Recruiting -
CHU de Nantes
Nantes, France Recruiting -
CH Pitié Salpêtrière
Paris, France Recruiting -
Hôpital Necker
Paris, France Recruiting -
CHU de Saint-Etienne
Saint-Etienne, France Recruiting -
CHU Strasbourg
Strasbourg, France Recruiting
Study contacts
- Study coordinator: Shams RIBAULT, MD
- Email: shams.ribault@chu-lyon.fr
- Phone: 00334 72 07 25 73
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Tremor in Charcot–Marie–Tooth disease
Try to characterize tremor in adults with Charcot–Marie–Tooth (CMT) disease using surface electromyography, accelerometers, a clinical exam and questionnaires to see how tremor affects daily life.
-
Behavioral parent-training with HOT DOCS and DOCS K-5 for caregivers of children ages 0–12.
This program tests whether group HOT DOCS and DOCS K-5 parent-training classes can help caregivers of children ages 0–12 reduce common challenging behaviors like tantrums, whining, and noncompliance.
-
Two-week intensive brain-focused therapy program for children with neurodevelopmental and chromosomal conditions
This program will try a two-week, individualized multimodal neurorehabilitation approach for children about 4–12 years old with neurodevelopmental or chromosomal conditions to see if it improves attention, motor skills, communication, and daily functioning.
-
rTMS plus personalized language training to help preschoolers with global developmental delay improve speech and communication
This study tries non‑invasive repetitive transcranial magnetic stimulation (rTMS) together with personalized language training to improve language in children aged 2–5 with global developmental delay.
-
Project PENGUIN: Profiling phenotypic, epigenetic, and neurogenetic traits in rare neurodevelopmental disorders
This project will try to collect clinical data, genetic and epigenetic samples, imaging, and skin-derived cell models from people with rare neurogenetic disorders like SYT1/BAGOS to help track disease and support future treatments.
-
High-tech rehabilitation program for adults with chronic neuromuscular diseases
This trial will test whether a high-tech rehab program using robotic systems, virtual reality, and balance platforms works as well as traditional rehab to reduce fatigue and improve function in adults with chronic neuromuscular diseases.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.